Navigation Links
Missouri Man Alleges Five Years of Actos Use Caused his Bladder Cancer; Parker Waichman LLP Files Lawsuit on Victim’s Behalf
Date:5/8/2013

New York, NY (PRWEB) May 08, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Missouri man who developed bladder cancer, allegedly from using Actos. The suit was filed on April 2, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0705), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos on or before May 20, 2004 through on or after July 18, 2009, about which time he stopped taking the drug and had developed bladder cancer, allegedly as a result of taking Actos. The Defendants allegedly knew that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. He is seeking damages for permanent injuries, emotional distress, economic loss due to medical expenses and living-related expenses due to a new lifestyle.

Thousands of Actos lawsuits have been filed in state and federal courts across the country, according to an April 16, 2013, Bloomberg report. Actos is a Type 2 diabetes medication that was approved by the U.S. Food and Drug Administration in 1999. In 2011, the agency updated the label to warn that users may face an increased risk of bladder cancer after taking the drug for only one year.

Since then, research has continued to suggest that Actos is associated with bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. Then, the July 3, 2012 Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/Actos_lawsuit_Sailor/05/prweb10715147.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Majority of Missouri tan salons allow pre-teens
2. Hormone Replacement Clinic, Renew Health and Wellness Opens in St. Louis, Missouri Area. New Center Specializes in Anti-Aging Therapies for both Women and Men.
3. InsuranceCalculator.net Now Provides Competitive Car Insurance Quotes To Missouri Drivers
4. Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
5. Wisconsin Woman Alleges She was Injured by Transvaginal Mesh Devices in Lawsuit Filed by Parker Waichman LLP
6. Skechers Lawsuit Filed By Wright & Schulte on Behalf of an Alabama Woman Alleges Serious Ankle Injury Was Caused by The Design of Skechers Shape-Ups
7. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
8. New Lawsuit Alleges Fosamax Increases Risk of Injury: Now, AttorneyOne Can Provide Advice
9. New Lawsuit alleges Actos caused Bladder Cancer
10. New Lawsuit Alleges Teen Molestation by Ex-Deputy
11. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: